Baxdrostat: A Novel Aldosterone Synthase Inhibitor for Treatment Resistant Hypertension

Curr Probl Cardiol. 2023 Nov;48(11):101918. doi: 10.1016/j.cpcardiol.2023.101918. Epub 2023 Jul 2.


Hypertension is a global epidemic, affecting around 30.4% of the population and being the leading preventable risk factor for death. Despite the availability of numerous antihypertensive agents, less than 20% of individuals have their blood pressure controlled. Resistant hypertension poses a challenge, but a new class of medication, aldosterone synthase inhibitors (ASI), shows promise. ASI reduces aldosterone production by inhibiting aldosterone synthase. This review article focuses on Baxdrostat, a highly potent ASI currently in phase 3 trials. It discusses the drug's biochemical pathway, efficacy trials in animals and humans, and its potential in uncontrolled hypertension, chronic kidney disease, and primary aldosteronism.

Publication types

  • Review

MeSH terms

  • Aldosterone* / therapeutic use
  • Animals
  • Antihypertensive Agents / pharmacology
  • Antihypertensive Agents / therapeutic use
  • Cytochrome P-450 CYP11B2
  • Humans
  • Hypertension* / drug therapy
  • Mineralocorticoid Receptor Antagonists / pharmacology
  • Mineralocorticoid Receptor Antagonists / therapeutic use


  • Aldosterone
  • Cytochrome P-450 CYP11B2
  • Antihypertensive Agents
  • Mineralocorticoid Receptor Antagonists